US Pharma MarketingThe Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.
BioMarin acquires experimental drug for rare bone disorder in $275M deal
The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.
Source: BioPharma Dive